EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma

Hua Ni, Xinjia Ding, Shikai Wu, Xuan Jin

Pathology and Oncology Research · 2023

DOI: 10.3389/pore.2023.1611330 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pathology and Oncology Research, 2023. Verfasst von Hua Ni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Capillary Leak Syndrome, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic capillary leak syndrome (SCLS) is a rare and complex adverse effect of immune checkpoint inhibitors (ICIs). The diagnosis of drug-induced SCLS is based on diffuse infusions of exudative fluid into the interstitial areas and the exclusion of other causes. The best management of ICIs-induced SCLS is not settled, though proper supportive care and corticosteroids were commonly applied as the first-line treatment. In our patient with advanced gastroesophageal junction squamous cell carcinoma, although ICIs-induced SCLS was successfully controlled with corticosteroids, the patient soon experienced cancer progress and died of pulmonary infections. Based on our experience and the reported cases by other hospitals, different stages of SCLS might respond differently to the same treatment. Therefore, a grading of ICIs-induced SCLS might help to stratify the patient for different treatment strategies. Besides, corticosteroids-sensitive patients, though waived from deadly SCLS, might be at higher risk of cancer progress and subsequent infections due to the application of corticosteroids. Considering that the inflammatory factors should be closely involved in the development of ICIs-induced SCLS, targeted therapy against the driver inflammatory cytokine might offer treatment regimens that are more effective and safer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Capillary Leak SyndromeCarcinoma, Squamous CellHumansAntibodies, Monoclonal, HumanizedAdrenal Cortex Hormones

Stichwörter der Autor:innen

SCLSadverse effectimmune checkpoint inhibitorpembrolizumabsystemic capillary leak syndrome

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Medical Oncology, Peking University First Hospital, Beijing, China.

Zitieren

APA

Ni, H., Ding, X., Wu, S., & Jin, X. (2023). Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma. Pathology and Oncology Research. https://doi.org/10.3389/pore.2023.1611330

Vancouver

Ni H, Ding X, Wu S, Jin X. Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma. Pathology and Oncology Research. 2023. doi:10.3389/pore.2023.1611330

BibTeX
@article{Ni2023,
  author = {Ni, Hua and Ding, Xinjia and Wu, Shikai and Jin, Xuan},
  title = {Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma},
  journal = {Pathology and Oncology Research},
  year = {2023},
  doi = {10.3389/pore.2023.1611330}
}
Kostenlos starten →